X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (285) 285
index medicus (254) 254
female (249) 249
male (243) 243
oncology (233) 233
middle aged (231) 231
aged (206) 206
adult (194) 194
cancer (135) 135
chemotherapy (122) 122
prognosis (86) 86
treatment outcome (82) 82
aged, 80 and over (73) 73
disease-free survival (70) 70
research (66) 66
antineoplastic combined chemotherapy protocols - therapeutic use (65) 65
adenocarcinoma (59) 59
metastasis (59) 59
survival (59) 59
care and treatment (58) 58
gastric cancer (58) 58
retrospective studies (58) 58
stomach cancer (53) 53
mutation (52) 52
therapy (52) 52
stomach neoplasms - pathology (49) 49
young adult (49) 49
analysis (48) 48
carcinoma (45) 45
patients (44) 44
tumors (44) 44
immunohistochemistry (43) 43
neoplasm staging (42) 42
cancer research (40) 40
kaplan-meier estimate (40) 40
pathology (40) 40
stomach neoplasms - drug therapy (40) 40
medicine & public health (39) 39
pharmacology & pharmacy (39) 39
survival rate (39) 39
neoplasm metastasis (38) 38
medical colleges (37) 37
expression (36) 36
fluorouracil (36) 36
research paper (36) 36
original article (35) 35
antineoplastic agents - therapeutic use (34) 34
medicine (34) 34
stomach neoplasms - genetics (34) 34
antineoplastic combined chemotherapy protocols - adverse effects (33) 33
hematology (33) 33
clinical trials (32) 32
colorectal cancer (32) 32
follow-up studies (32) 32
survival analysis (32) 32
adolescent (31) 31
capecitabine (31) 31
cisplatin (31) 31
deoxycytidine - analogs & derivatives (31) 31
genetic aspects (31) 31
risk factors (31) 31
trial (31) 31
original (30) 30
deoxycytidine - administration & dosage (29) 29
pharmacology/toxicology (29) 29
research article (29) 29
health aspects (28) 28
oncology, experimental (28) 28
cell biology (27) 27
drug therapy (27) 27
fluorouracil - administration & dosage (27) 27
mutations (27) 27
oxaliplatin (27) 27
surgery (27) 27
adenocarcinoma - drug therapy (26) 26
cancer therapies (26) 26
gene amplification (26) 26
gene expression (26) 26
genetics (26) 26
leucovorin (26) 26
studies (26) 26
disease progression (25) 25
multidisciplinary sciences (25) 25
genes (24) 24
patient outcomes (24) 24
stomach neoplasms - mortality (24) 24
combination (23) 23
lung neoplasms - drug therapy (23) 23
multicenter (23) 23
prospective studies (23) 23
cancer patients (22) 22
gemcitabine (22) 22
metastases (22) 22
neoplasms (22) 22
breast-cancer (21) 21
cisplatin - administration & dosage (21) 21
medical prognosis (21) 21
neoplasms. tumors. oncology. including cancer and carcinogens (21) 21
antimitotic agents (20) 20
antineoplastic agents (20) 20
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastroenterology, ISSN 0016-5085, 05/2018, Volume 154, Issue 6, pp. S-278 - S-278
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 2, pp. 181 - 188
Summary Background Combination chemotherapy with gemcitabine and a platinum-based agent is regarded as a standard treatment for patients with advanced... 
Hematology, Oncology and Palliative Medicine | PLUS GEMCITABINE | CHOLANGIOCARCINOMA | CISPLATIN | ONCOLOGY | ADENOCARCINOMA | PANCREATIC-CANCER | CLINICAL-TRIALS | II TRIAL | COMBINATION | CHEMOTHERAPY | GALL-BLADDER CANCER | Erlotinib Hydrochloride | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Deoxycytidine - therapeutic use | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Deoxycytidine - adverse effects | Female | Quinazolines - administration & dosage | Biliary Tract Neoplasms - drug therapy | Biliary Tract Neoplasms - pathology | Gallbladder Neoplasms - epidemiology | Cholangiocarcinoma - epidemiology | Deoxycytidine - administration & dosage | Biliary Tract Neoplasms - epidemiology | Disease Progression | Disease-Free Survival | Cholangiocarcinoma - pathology | Gallbladder Neoplasms - drug therapy | Cholangiocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Aged | Gallbladder Neoplasms - pathology | Neoplasm Staging | Organoplatinum Compounds - therapeutic use | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Medical colleges | Chemotherapy | Erlotinib | Gemcitabine | Pancreatic cancer | Oncology, Experimental | Clinical trials | Research | Drug therapy, Combination | Cancer
Journal Article
Nature Medicine, ISSN 1078-8956, 05/2015, Volume 21, Issue 5, pp. 449 - 456
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 10/2015, Volume 10, Issue 10, p. e0140712
Journal Article
Journal Article
Nature Medicine, ISSN 1078-8956, 09/2018, Volume 24, Issue 9, pp. 1449 - 1458
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 11, pp. 1125 - 1132
Journal Article
by Fritsche, Lars G and Igl, Wilmar and Bailey, Jessica N. Cooke and Grassmann, Felix and Sengupta, Sebanti and Bragg-Gresham, Jennifer L and Burdon, Kathryn and Hebbring, Scott J and Wen, Cindy and Gorski, Mathias and Kim, Ivana K and Cho, David and Zack, Donald and Souied, Eric and Scholl, Henik and Bala, Elisa and ELee, Kristine and Hunter, David J and Sardell, Rebecca J and Mitchell, Paul and Merriam, Joanna E and Cipriani, Francesco and Hoffman, Joshua D and Schick, Tina and Lechanteur, Yara T.E and Guymer, Robyn and Johnson, Matthew and Jiang, Yingda and Stanton, Chloe M and Buitendijk, Gabrielle and Zhan, Xiaowei and Kwong, Alan M and Boleda, Alexis and Brooks, Matthew and Gieser, Linn and Ratna Priya, Rinki and Branham, Kari E and Foerster, Johanna R and Heckenlively, John R and Othman, Mohammad I and Vote, Brendan J and Liang, Helena Hai and Souzeau, Emmanuelle and McAllister, Ian L and Isaacs, Timothy and Hall, Janette and Lake, Stewart and Mackey, David A and Constable, Ian J and Craig, Jamie E and Kitchner, Terrie E and Yang, Zhenglin and Su, Zhiguang and Luo, Hongrong and Chen, Daniel and Ouyang, Hong and Flagg, Ken and Lin, Danni and Mao, Guanping and Ferreyra, Henry and Stark, Klaus and Strachwitz, Claudia and Wolf, Armin and Brandl, Caroline and Rudolph, Guenther and Olden, Matthias and Morrison, Margaux A and Morgan, Denise and Schu, Matthew and Ahn, Jeeyun and Silvestri, Giuliana and ETsironi, Evangelia and Park, Kyu Hyung and Farrer, Lindsay and Orlin, Anton and Brucker, Alexander and Li, Mingyao and Curcio, Christine A and Mohand-Sa'd, Saddek and Sahel, José-Alain and Audo, Isabelle and Benchaboune, Mustapha and Cree, Angela and Rennie, Christina A and Goverdhan, Srinivas V and Grunin, Michelle and Hagbi-Levi, Shira and Campochiaro, Peter and Katsanis, Nicholas and Holz, Frank G and Blond, Frédéric and Blanché, Hél'ne and Deleuze, Jean-Fran'ois and Igo Jr., Robert and Truitt, Barbara and Peachey, Neal S and Meuer, Stacy M and Myers, Chelsea E and Moore, Emily L and Klein, Ronald and ...
Nature Genetics, ISSN 1061-4036, 02/2016, Volume 48, Issue 2, pp. 134 - 143
Journal Article
by Shitara, Kohei and Özgüroğlu, Mustafa and Bang, Yung-Jue and Di Bartolomeo, Maria and Mandalà, Mario and Ryu, Min-Hee and Fornaro, Lorenzo and Olesiński, Tomasz and Caglevic, Christian and Chung, Hyun C and Chung, Hyun Cheol and Muro, Kei and Goekkurt, Eray and Mansoor, Wasat and McDermott, Raymond S and Shacham-Shmueli, Einat and Chen, Xinqun and Chen, Jen-Shi and Mayo, Carlos and Kang, S Peter and Ohtsu, Atsushi and Fuchs, Charles S and Lerzo, Guillermo and O'Connor, Juan Manuel and Mendez, Guillermo Ariel and Lynam, James and Tebbutt, Niall and Wong, Mark and Strickland, Andrew and Karapetis, Chris and Goldstein, David and Vasey, Paul and Van Laethem, Jean-Luc and Van Cutsem, Eric and Berry, Scott and Vincent, Mark and Muller, Bettina and Rey, Felipe and Zambrano, Angela and Guerra, Joaquin and Krogh, Merete and Baeksgaard, Lene and Yilmaz, Mette and Elme, Anneli and Magi, Andrus and Auvinen, Paivi and Alanko, Tuomo and Moehler, Markus and Kunzmann, Volker and Seufferlein, Thomas and Thuss-Patience, Peter and Hoehler, Thomas and Haag, Georg and Al-Batran, Salah-Eddin and Castro, Hugo and Lopez, Karla and Aguilar Vasquez, Mynor and Sandoval, Mario and Lam, Ka On and Cuffe, Sinead and Kelly, Cathy and Geva, Ravit and Hubert, Ayala and Beny, Alex and Brenner, Baruch and Giuseppe, Aprile and Falcone, Alfredo and Maiello, Evaristo and Passalacqua, Rodolfo and Montesarchio, Vincenzo and Hara, Hiroki and Chin, Keisho and Nishina, Tomohiro and Komatsu, Yoshito and Machida, Nozumo and Hironaka, Shuichi and Satoh, Taroh and Tamura, Takao and Sugimoto, Naotaoshi and Cho, Haruhiko and Omuro, Yashushi and Kato, Ken and Goto, Masahiro and Hyodo, Ichinosuke and Yoshida, Kazuhiro and Baba, Hideo and Esaki, Taito and Furuse, Junji and Wan Mohammed, Wan Zamaniah and Hernandez Hernandez, Carlos and Casas Garcia, Juan and Dominguez Andrade, Adriana and Clarke, Katriona and Hjortland, Geir and Glenjen, Nils and Kubiatowski, Tomasz and Jacek, Jassem and Wojtukiewicz, Marek and Lazarev, Sergey and Lancukhay, Yuri and ... and KEYNOTE-061 Investigators and KEYNOTE-061 investigators
The Lancet, ISSN 0140-6736, 07/2018, Volume 392, Issue 10142, pp. 123 - 133
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2019, Volume 9, Issue 1, pp. 1 - 8
We investigated risk factors for immune-related adverse events (irAEs) in patients treated with anti-programmed cell death protein1 antibody pembrolizumab. A... 
Body mass index | Pembrolizumab | Pneumonitis | PD-1 protein | Cell death | Endocrine diseases | Regression analysis | Patients | Risk factors | Apoptosis
Journal Article